US$14 b is AU$160 per share for Neuren.I think you are right that similar deal would be reasonable for Neuren in not too distant future.
Analysts estimated $2 billion peak sales potential for Karuna drug for Schizophrenia if approved.
Trof peak sales likely $1 billion now and NNZ-2591 for 4 current Ph 2 indications been said to be 5x market size ie $5 billion. Which is 2.5x for Karuna drug.They just completed Ph 3 of course, and we are still Ph 2. But if you add a 60% discount for that you'd end up same place as Karuna.
I personally believe any takeover will be over 100. And if Neuren keep pushing it could be $150 or more potentially.
Bristol Myers to acquire Karuna for $14Billion, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.550(3.71%) |
Mkt cap ! $1.915B | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.50 | $14.91 | $9.641M | 631.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $15.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 1224 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |